The global medical technology and healthcare products industry is facing a period of severe turbulence. Ongoing geopolitical tensions in Eastern Europe and the Middle East, combined with logistical supply chain bottlenecks and the complex transition toward the MDR/IVDR framework in Europe, are forcing manufacturers to redefine their geographical expansion strategies. In this quest for stable, dynamic, and growth markets, Latin America appears as a premier strategic destination.
Long perceived as a fragmented ecosystem, the region is undergoing a profound structural transformation. While a centralized, single market akin to the European Union does not exist, a clear regional dynamic has taken shape: Latin American sanitary agencies are actively modernizing and aligning their regulatory requirements with the standards of the world’s most mature healthcare markets. For international manufacturers, this regulatory convergence creates effective operational gateways.
How do global geopolitics shift healthcare investment today?
Market access decisions are no longer evaluated solely on a country’s commercial potential; they now integrate critical variables of geopolitical risk and regulatory predictability. Ongoing conflicts and macroeconomic instability across traditional export regions are prompting MedTech and pharmaceutical executives to look for predictable, secondary regional markets.
Fortunately, Latin America offers a highly compelling alternative. Boasting a combined population of over 650 million, rapidly rising urbanization, and increasing public and private investments to modernize healthcare infrastructure, the region’s demand for high-tech medical devices and innovative therapies is structural. The relative stability of the continent, combined with a unified political will to ease access to healthcare technologies, transforms Latam into a highly attractive, predictable growth harbor for manufacturers.
Why is regulatory convergence accelerating regional alignment?
International manufacturers must recognize that there is no single, unified regulatory approval that grants universal distribution rights in Mexico, Brazil or Chile. Each sovereign nation keeps its own competent sanitary authority such as ANVISA in Brazil, COFEPRIS in Mexico, or the ISP in Chile and enforces its own distinct legal framework.
However, technical divergence is systematically decreasing. In fact, sanitary agencies are integrating international benchmarks into their domestic legislation. Thus, the region is witnessing a major shift away from purely bureaucratic, administrative controls toward sophisticated risk-management systems heavily inspired by the guidelines of the International Medical Device Regulators Forum (IMDRF). This widespread adoption of common technical benchmarks establishes a similar technical foundation from one country to the next.
Which international standards serve as integrated technical pillars?
The alignment of sanitary agencies across Latam relies on the adoption of international standards:
The Medical Device Single Audit Program (MDSAP)
MDSAP stands for one of the most tangible regulatory gateways in operation. This program allows a single quality management system (QMS) audit conducted by an authorized auditing organization to satisfy the regulatory requirements of multiple participating authorities worldwide (including the United States, Canada, Australia, and Japan).
In Latin America, Brazil’s ANVISA is a prominent founding member of MDSAP. Thus, ANVISA utilizes MDSAP audit reports to substitute its own domestic Brazilian Good Manufacturing Practices (BGMP) inspections, drastically accelerating the registration timeline. Other agencies in the region actively observe this program or eventually integrate these audit findings into their local evaluations.
ISO Standards as the global technical benchmark
ISO 13485 (Medical devices quality management system) and ISO 14971 (Medical devices risk management application) are the undisputed pillars of technical dossiers across Latam. Whether a manufacturer is submitting a registration to COFEPRIS or ANVISA, the structure of design data, sterilization validations, and software verifications relies on these identical standards. A robust technical file constructed following the IMDRF’s Summary Technical Documentation (STED) format requires minimal technical modification when transitioning from one Latin American agency to another.
How does regulatory reliance build mutual trust between authorities?
One of the most effective levers implemented by Latin American sanitary authorities to optimize internal resources and accelerate patient access to medical innovations is the principle of regulatory reliance. Intermediate or rapidly modernizing agencies leverage the scientific evaluations, audit reports, and approvals generated by mature National Regulatory Authorities (NRAs), as they share critical safety data.
COFEPRIS Equivalence Decrees in Mexico
Mexico pioneered expedited pathways through legal decrees. COFEPRIS formally recognizes market authorizations previously granted by the US FDA, Health Canada, Japan’s MHLW, and specific European CE markings under designated conditions. When a medical device already possesses one of these reference approvals, the review process in Mexico is streamlined via an expedited pathway, significantly reducing approval timelines compared to a standard local submission.
Lear more about the last regulatory updates: https://www.mandala-intl.com/en/regulatory-updates/mexico-fast-track-medical-device-registration-cofepris-30-days/
The Chilean Exempt Decree No. 25
In Chile, the Institute of Public Health (ISP) applies a matching logic, reinforced by recent regulatory evolutions such as Exempt Decree No. 25. For specific categories of medical devices, presenting a Certificate of Free Sale (CFS) or a registration certificate from a high-surveillance country (such as the EU, US, Canada, Australia, or Brazil) allows the manufacturer to bypass certain local technical evaluation phases. This enables the ISP to focus its resources primarily on labeling compliance, regional traceability, and local technovigilance.
Lear more about the last regulatory updates: https://www.mandala-intl.com/en/regulatory-updates/chile-medical-device-ivd-regulations-isp-registration/
Practical impact for manufacturers: Optimizing regional dossier compilation
For regulatory affairs departments, this practical harmonization completely redefines international deployment methods. Previously, entering five distinct Latin American markets required drafting five entirely separate technical dossiers and managing redundant local testing.
Today, the best practice strategy dictates the creation of a regional core dossier. This centralized technical repository stores global data:
- Quality Management System certification (ideally ISO 13485 and the MDSAP audit report).
- Biocompatibility test reports (ISO 10993 series), electrical safety data (IEC 60601 series), and performance validation records.
- Global clinical evaluation data.
Once this technical core is validated for a primary reference market in the region (usually, Brazil or Mexico first), adapting it for Colombia (INVIMA), Chile (ISP), or Peru (DIGEMID) become an administrative task (translation, labeling adaptation in Spanish or Portuguese). Consequently, the time-to-market and compliance costs for subsequent target countries are frequently reduced by half.
The strategic role of the Pacific Alliance and regional blocs
Beyond unilateral agency initiatives, multilateral political alliances are actively working to fluidify the trade of healthcare products. The Pacific Alliance, including Mexico, Colombia, Chile, and Peru, includes a dedicated working group focused on regulatory cooperation for medical devices and cosmetics.
The long-term objective of these sector-specific agreements is the elimination of technical barriers to trade. This is achieved by harmonizing dossier presentation formats, aligning post-market technovigilance guidelines and exploring mutual recognition mechanisms for Good Manufacturing Practices (GMP) inspections.
While the integration process is gradual, it reflects a definitive regional commitment to economic and sanitary alignment.
Why is local technical expertise mandatory for your expansion strategy?
Capitalizing on these gateways requires an expert understanding of the localized nuances that persist despite harmonization. Technical convergence does not eliminate administrative strictness.
- The Choice of a registration holder: In nearly all Latin American authorities requires a local legal entity. Manufacturers benefit from decoupling their regulatory assets from their commercial distributors by using an independent third-party registration holder such as Mandala International. This strategic approach ensures total control over intellectual property rights and grants the flexibility to change commercial distributors without market access interruption.
- Administrative compliance and legalizations: While agencies align on technical content, administrative protocols remain highly formal. Legal documents, such as Certificates of Free Sale and Letters of Authorization, must be properly apostilled or legalized in accordance with the Hague Convention to be considered legally valid by local reviewers.
- Rigorous technical translation: Clinical evaluations, instructions for use (IFU), and labeling must be translated into Spanish (or Portuguese for Brazil) with flawless technical accuracy. Poorly executed translations are still a primary cause of formal clarification requests from regulatory evaluators, creating avoidable delays in the approval process.
Are Latam markets opening new commercial opportunities?
Regulatory harmonization in Latin America is an active operational reality. Indeed, by aligning their technical requirements with international standards and using robust reliance mechanisms with global reference authorities, Latin American markets are substantially lowering entry barriers for international medical device and healthcare product manufacturers.
In a global economic climate where market diversification is paramount for corporate resilience, the Latam region has successfully transitioned from a secondary commercial market into a prioritized investment zone.
SAVE TIME & MONEY WITH MANDALA INTERNATIONAL'S LATAM EXPANSION PACK
Mandala International’s Latam Expansion Pack is the ultimate shortcut designed to slash your compliance costs and crush your time-to-market goals! We exploit every single reliance pathway and equivalence decree to improve your technical dossiers. By consolidating all your registrations under one dominant independent partner, you instantly eliminate expensive administrative overlap and stop paying for redundant local tests.
Don’t let your competitors steal the market! Save your budget and launch across multiple Latin American countries simultaneously at unbeatable speed.
By submitting this form, you agree to be contacted by Mandala International and to receive related communications.
About Mandala International
Mandala International is a regulatory and market access partner specialized in Latin America, supporting manufacturers of regulated health products throughout the product registration and commercialization process.
With expertise across Brazi, Mexico, Colombia, Peru and Chile, Mandala International helps companies navigate regulatory frameworks, obtain product approvals, and successfully access Latin American healthcare markets.
Q&A - Navigating health product launches in Latin America
Regulatory reliance describes a process where one sanitary authority leverages evaluations from another reference agency. Specifically, intermediate healthcare regulators review existing approvals from mature national regulatory authorities. This mechanism allows agencies to skip redundant local technical file evaluation phases. Consequently, it accelerates patient access to international medical devices while optimizing public administrative resources.
Yes, Brazil’s ANVISA accepts MDSAP audit reports to substitute local factory inspections. As a founding member, the Brazilian authority uses these unified quality management system records. This participation entirely eliminates the traditional requirement for a distinct, domestic GMP inspection. Ultimately, using this global audit pathway slashes manufacturing registration timelines by several months.
Mexico’s COFEPRIS equivalence decrees formally recognize foreign medical device authorizations. For instance, the agency accepts valid US FDA, Health Canada, and Japanese MHLW certifications. Presenting these reference credentials triggers a streamlined administrative review instead of a full technical evaluation.
Furthermore, COFEPRIS recently launched a major Abbreviated Regulatory Pathway (Fast-Track). This international reliance framework dramatically upgrades Mexican market access:
- 30-Day Commitment: COFEPRIS formally resolves fast-track equivalency submissions within 30 working days.
- Global Alignment: The pathway uses simplified registers accepting approvals from the US FDA, Health Canada, European Union (MDR), ANVISA (Brazil), MHRA (UK), and TGA (Australia).
- Strict Identity: The medical device must remain entirely identical to the version authorized by the reference agency.
For a deeper dive into the specific requirements, read our last regulatory updates: https://www.mandala-intl.com/en/regulatory-updates/mexico-fast-track-medical-device-registration-cofepris-30-days/
A single universal technical dossier does not grant direct access across Latin America. Each sovereign nation keeps independent sanitary laws and distinct local administrative protocols.
However, you can easily bypass this barrier by centralizing your regional expansion with Mandala International. By using our Latam Expansion Pack, you take full advantage of a powerful internal regulatory gateway. This exclusive solution allows you to use a shared technical baseline file for Brazil, Mexico, Colombia, Peru and Chile.
To learn more about optimizing your technical files, check out our solution: https://www.mandala-intl.com/en/latam-expansion-pack/
